Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash from Financing Activities (2020 - 2025)

Xeris Biopharma Holdings' Cash from Financing Activities history spans 6 years, with the latest figure at -$266000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 166.83% year-over-year to -$266000.0, compared with a TTM value of $11.4 million through Dec 2025, down 68.51%, and an annual FY2025 reading of $11.4 million, down 68.51% over the prior year.
  • Cash from Financing Activities for Q4 2025 was -$266000.0 at Xeris Biopharma Holdings, down from $13.8 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $78.2 million in Q1 2022, with the low at -$3.1 million in Q1 2025.
  • Average Cash from Financing Activities over 5 years is $10.0 million, with a median of $354000.0 recorded in 2022.
  • Biggest YoY gain for Cash from Financing Activities was 39224.8% in 2022; the steepest drop was 18800.0% in 2022.
  • Tracing XERS's Cash from Financing Activities over 5 years: stood at $125000.0 in 2021, then skyrocketed by 39224.8% to $49.2 million in 2022, then tumbled by 102.51% to -$1.2 million in 2023, then surged by 132.25% to $398000.0 in 2024, then tumbled by 166.83% to -$266000.0 in 2025.
  • Per Business Quant, the three most recent readings for XERS's Cash from Financing Activities are -$266000.0 (Q4 2025), $13.8 million (Q3 2025), and $942000.0 (Q2 2025).